Dr Reddy's Laboratories Gross Margin 2010-2024 | RDY

Current and historical gross margin for Dr Reddy's Laboratories (RDY) over the last 10 years. The current gross profit margin for Dr Reddy's Laboratories as of June 30, 2024 is %.
Dr Reddy's Laboratories Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2024-06-30 $3.45B $2.04B 59.04%
2024-03-31 $3.35B $1.96B 58.60%
2023-12-31 $3.23B $1.89B 58.34%
2023-09-30 $3.19B $1.87B 58.53%
2023-06-30 $3.15B $1.85B 58.64%
2023-03-31 $2.99B $1.70B 56.68%
2022-12-31 $2.95B $1.64B 55.65%
2022-09-30 $2.83B $1.54B 54.16%
2022-06-30 $2.82B $1.49B 52.58%
2022-03-31 $2.83B $1.50B 53.15%
2021-12-31 $2.83B $1.51B 53.32%
2021-09-30 $2.79B $1.49B 53.30%
2021-06-30 $2.67B $1.43B 53.43%
2021-03-31 $2.59B $1.41B 54.32%
2020-12-31 $2.38B $1.28B 53.80%
2020-09-30 $2.32B $1.25B 53.88%
2020-06-30 $2.34B $1.29B 54.89%
2020-03-31 $2.32B $1.25B 53.80%
2019-12-31 $2.46B $1.33B 54.10%
2019-09-30 $2.38B $1.29B 54.06%
2019-06-30 $2.24B $1.19B 53.26%
2019-03-31 $2.23B $1.21B 54.25%
2018-12-31 $2.15B $1.17B 54.52%
2018-09-30 $2.20B $1.21B 55.16%
2018-06-30 $2.21B $1.21B 54.73%
2018-03-31 $2.18B $1.17B 53.74%
2017-12-31 $2.26B $1.21B 53.27%
2017-09-30 $2.22B $1.20B 53.87%
2017-06-30 $2.21B $1.20B 54.51%
2017-03-31 $2.17B $1.21B 55.60%
2016-12-31 $2.09B $1.19B 56.89%
2016-09-30 $2.15B $1.23B 57.10%
2016-06-30 $2.22B $1.30B 58.57%
2016-03-31 $2.34B $1.39B 59.70%
2015-12-31 $2.43B $1.45B 59.70%
2015-09-30 $2.44B $1.45B 59.36%
2015-06-30 $2.40B $1.40B 58.39%
2015-03-31 $2.40B $1.39B 57.93%
2014-12-31 $2.36B $1.35B 57.41%
2014-09-30 $2.32B $1.34B 57.99%
2014-06-30 $2.27B $1.32B 58.14%
2014-03-31 $2.17B $1.23B 56.65%
2013-12-31 $2.20B $1.22B 55.57%
2013-09-30 $2.15B $1.15B 53.35%
2013-06-30 $2.16B $1.12B 52.11%
2013-03-31 $2.14B $1.12B 52.20%
2012-12-31 $2.05B $1.11B 54.47%
2012-09-30 $2.05B $1.16B 56.48%
2012-06-30 $1.96B $1.10B 55.99%
2012-03-31 $1.95B $1.10B 56.26%
2011-12-31 $1.88B $1.02B 54.01%
2011-09-30 $1.78B $0.94B 52.55%
2011-06-30 $1.74B $0.94B 53.82%
2011-03-31 $1.66B $0.89B 53.49%
2010-12-31 $1.57B $0.82B 52.04%
2010-09-30 $1.52B $0.78B 51.02%
2010-06-30 $1.48B $0.73B 48.89%
2010-03-31 $1.50B $0.75B 49.70%
2009-12-31 $1.53B $0.86B 56.03%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $12.399B $3.350B
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00